In Vivo 11β-Hydroxysteroid Dehydrogenase Inhibition in Posaconazole-Induced Hypertension and Hypokalemia-Reference-Cited by-同舟云学术

In Vivo 11β-Hydroxysteroid Dehydrogenase Inhibition in Posaconazole-Induced Hypertension and Hypokalemia

Published:2017-08 Issue:8 Volume:61 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Thompson George R.¹²,Chang Diana³,Wittenberg Rebecca R.⁴,McHardy Ian¹,Semrad Alison⁵

Affiliation:

1. Department of Medical Microbiology and Immunology, University of California–Davis, Davis, California, USA

2. Department of Internal Medicine, Division of Infectious Diseases, University of California Davis Medical Center, Davis, California, USA

3. Department of Internal Medicine, University of California Davis Medical Center, Davis, California, USA

4. Department of Pharmacy, University of California Davis Medical Center, Davis, California, USA

5. Department of Internal Medicine, Division of Endocrinology, University of California Davis Medical Center, Davis, California, USA

Abstract

ABSTRACT We describe a case of apparent mineralocorticoid excess (AME) secondary to posaconazole therapy and suggest the biochemical mechanism. Clinical and laboratory investigation confirmed 11β-hydroxysteroid dehydrogenase inhibition and withholding therapy led to a resolution of all clinical and laboratory abnormalities. Posaconazole was later restarted at a lower dose and prevented recurrence of this syndrome. Additional studies are necessary to determine the frequency of posaconazole-induced AME and whether other azole antifungals can be associated with this phenomenon.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00760-17

Reference16 articles.

1. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

2. Switching from Posaconazole Suspension to Tablets Increases Serum Drug Levels in Leukemia Patients without Clinically Relevant Hepatotoxicity

3. Treatment of Invasive Aspergillosis with Posaconazole in Patients Who Are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled Trial

4. Inhibition of 11β-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of the potential risk of oteseconazole and two other tetrazole antifungals to inhibit adrenal steroidogenesis and peripheral metabolism of corticosteroids;Frontiers in Pharmacology;2024-08-08

2. Azole Antifungal Drug Toxicity-A Review;J BIOL REG HOMEOS AG;2024

3. Successful Treatment of Paecilomyces variotii Pneumonia and Lupus Nephritis With Posaconazole-Cyclophosphamide Co-administration Without Drug Interaction–Induced Toxicity;Open Forum Infectious Diseases;2023-08-01

4. Characterization of the interferences of systemic azole antifungal drugs with adrenal steroid biosynthesis using H295R cells and enzyme activity assays;Current Research in Toxicology;2023

5. Hypoaldosteronism, pseudohypoaldosteronism and salt loss;Steroids in the Laboratory and Clinical Practice;2023